Document Type
Poster
Publication Date
2024
Abstract
Our team is developing a microsphere formulation to control the release of etonogestrel, targeting a 6- to 12-month duration, steady hormone dose, and a rapid drop in plasma concentrations at end of duration. It is unclear how acceptable the LAI will be given specific attributes, which duration(s) women prefer, and how LAI acceptability/preferences vary between different end-users. End-user research is critical across the full product development and implementation process.
Recommended Citation
Gottert, Ann, Timothy Abuya, Elizabeth Proos, Isabella Johnson, Nathan H. Dormer, Uli Foley, Grace Saul, Lisa B. Haddad, and David R. Friend. "Acceptability of and Preferences for Long-Acting Injectable Hormonal Contraception: Results from a National Online Survey with US Women." Poster presentation at Society for Family Planning 2024, 29-21 October, Detroit, Michigan.
Language
English